CHMP recommends authorisation for Pfizer-BioNTech’s Covid-19 vaccine

28 Jun 2024
www.pharmaceutical-technology.com
Drug ApprovalVaccineEmergency Use Authorization
CHMP recommends authorisation for Pfizer-BioNTech’s Covid-19 vaccine
Preview
Source: Pharmaceutical Technology
BioNTech is the marketing authorisation holder of the COMIRNATY vaccine. Credit: Martin Podzorny / Shutterstock.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for Pfizer and BioNTech’s Omicron JN 1-adapted monovalent Covid-19 vaccine, COMIRNATY JN 1.
The vaccine is intended for active immunisation against the infection in people aged six months and above.
The World Health Organization’s Technical Advisory Group on COVID-19 Vaccine Composition and the European Medicines Agency’s Emergency Task Force (ETF) recently advised updating vaccines to address the JN 1 variant for the 2024 to 2025 vaccination campaign.
The ETF highlighted that “evidence indicates that targeting JN 1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”
The European Commission (EC) is set to review the CHMP’s positive opinion and issue a final decision.
See Also:Verona scores FDA approval for Ohtuvayre as COPD maintenance therapy
CHMP recommends authorisation for Pfizer-BioNTech’s Covid-19 vaccine
Preview
Source: Pharmaceutical Technology
FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market
CHMP recommends authorisation for Pfizer-BioNTech’s Covid-19 vaccine
Preview
Source: Pharmaceutical Technology
Post the receipt of EC approval, the updated vaccine will be made available across European Union member states.
Pfizer and BioNTech proactively produced the Omicron JN 1-adapted vaccine to ensure immediate availability for the anticipated higher demand during the autumn and winter seasons of 2024 to 2025.
The CHMP’s endorsement is based on comprehensive clinical, non-clinical and real-world data supporting the efficacy and safety of Pfizer-BioNTech’s Covid-19 vaccinesCovid-19 vaccines.
The application comprised data demonstrating the JN 1-adapted vaccine’s potential to elicit a significantly enhanced response against Omicron JN 1 sublineages, surpassing the response from their Omicron XBB.1.5-adapted vaccine.
The companies are initiating rolling submissions with the US Food and Drug Administration seeking approval for Omicron KP.2-adapted vaccines in people aged six months and above.
BioNTech is the marketing authorisation holder of the COMIRNATY vaccine and its variants in regions including the US, the EU and the UK.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.